Intellia Therapeutics Company Profile (NASDAQ:NTLA)

About Intellia Therapeutics (NASDAQ:NTLA)

Intellia Therapeutics logoIntellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company's division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company's subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NTLA
  • CUSIP: N/A
  • Web: www.intelliatx.com
Capitalization:
  • Market Cap: $629.43 million
  • Outstanding Shares: 36,113,000
Average Prices:
  • 50 Day Moving Avg: $16.49
  • 200 Day Moving Avg: $14.48
  • 52 Week Range: $10.83 - $24.90
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.98
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $22.63 million
  • Price / Sales: 27.81
  • Book Value: $5.20 per share
  • Price / Book: 3.35
Profitability:
  • EBIDTA: ($45,440,000.00)
  • Net Margins: -204.48%
  • Return on Equity: -22.70%
  • Return on Assets: -16.17%
Debt:
  • Current Ratio: 9.33%
  • Quick Ratio: 9.33%
Misc:
  • Average Volume: 263,569 shs.
  • Beta: 2.86
  • Short Ratio: 9.17
 

Frequently Asked Questions for Intellia Therapeutics (NASDAQ:NTLA)

What is Intellia Therapeutics' stock symbol?

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

How were Intellia Therapeutics' earnings last quarter?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) issued its earnings results on Thursday, August, 3rd. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.42) by $0.04. The firm had revenue of $5.90 million for the quarter, compared to analysts' expectations of $5.83 million. Intellia Therapeutics had a negative return on equity of 22.70% and a negative net margin of 204.48%. The company's quarterly revenue was up 40.5% on a year-over-year basis. View Intellia Therapeutics' Earnings History.

Where is Intellia Therapeutics' stock going? Where will Intellia Therapeutics' stock price be in 2017?

8 brokers have issued 1 year price objectives for Intellia Therapeutics' shares. Their forecasts range from $20.00 to $36.00. On average, they expect Intellia Therapeutics' stock price to reach $26.80 in the next year. View Analyst Ratings for Intellia Therapeutics.

What are analysts saying about Intellia Therapeutics stock?

Here are some recent quotes from research analysts about Intellia Therapeutics stock:

  • 1. Cann analysts commented, "Loss per share was $0.45 compared to our estimated loss of $0.39. This was the result of lower than expected Collaborative revenue of $5.9 million compared to our estimate of $6.5 million and higher than estimated R&D expenses of $15.6 million compared to our estimated $14.1 million. Lower revenue and higher expenses were partially offset by a higher than estimated shares outstanding. There were no other meaningful variances in the quarter. Our outlook remains basically unchanged. We have made modest adjustments to our estimated shares outstanding and R&D expense." (8/1/2017)
  • 2. According to Zacks Investment Research, "Intellia Therapeutics, Inc. is a genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. Intellia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (4/18/2017)
  • 3. Chardan Capital analysts commented, "We initiate coverage of Intellia Therapeutics (NTLA) with a Buy rating (PT $19), on our view of possible downside driven by the company's IP weakness overridden by relative under-valuation of the CRISPR sector. Intellia is a preclinical biotech company aiming to treat various genetic conditions using the CRISPR-Cas9 gene editing system, in which a CRISPR guide RNA (gRNA) targets a Cas9 nuclease (a sort of "DNA scissors") to specifically modify a particular DNA sequence to treat diseases. Intellia's lead asset for transthyretin (TTR) amyloidosis, partnered with Neutral-rated Regeneron Pharmaceuticals, is guided to initiate IND-enabling studies by 2H17/1H18." (3/27/2017)

Who are some of Intellia Therapeutics' key competitors?

Who are Intellia Therapeutics' key executives?

Intellia Therapeutics' management team includes the folowing people:

  • Perry A. Karsen, Chairman of the Board
  • Nessan Bermingham, President, Chief Executive Officer, Founder, Director
  • Graeme Bell, Chief Financial Officer, Executive Vice President
  • Jose E. Rivera J.D., Executive Vice President, General Counsel
  • John M. Leonard M.D., Executive Vice President - Research and Development
  • Frank Verwiel M.D., Director
  • Caroline D. Dorsa, Independent Director
  • Jean-Francois Formela M.D., Independent Director
  • Carl L. Gordon Ph.D., Independent Director

When did Intellia Therapeutics IPO?

(NTLA) raised $85 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who owns Intellia Therapeutics stock?

Intellia Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Atlas Venture Associates IX LLC (10.35%), FMR LLC (8.94%), Vanguard Group Inc. (2.76%), Artal Group S.A. (0.69%), ARK Investment Management LLC (0.48%) and State Street Corp (0.46%). Company insiders that own Intellia Therapeutics stock include Bros Advisors Lp Baker, Carl L Gordon, Institutes For Biomed Novartis, Jean Francois Formela and Venture Fund Ix LP Atlas. View Institutional Ownership Trends for Intellia Therapeutics.

Who sold Intellia Therapeutics stock? Who is selling Intellia Therapeutics stock?

Intellia Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Tekla Capital Management LLC, Northern Trust Corp, Acadian Asset Management LLC and ProShare Advisors LLC. Company insiders that have sold Intellia Therapeutics stock in the last year include Jean Francois Formela and Venture Fund Ix LP Atlas. View Insider Buying and Selling for Intellia Therapeutics.

Who bought Intellia Therapeutics stock? Who is buying Intellia Therapeutics stock?

Intellia Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Vanguard Group Inc., OxFORD Asset Management LLP, GSA Capital Partners LLP, State Street Corp, TIAA CREF Investment Management LLC, Dimensional Fund Advisors LP and American Century Companies Inc.. Company insiders that have bought Intellia Therapeutics stock in the last two years include Bros Advisors Lp Baker, Carl L Gordon and Institutes For Biomed Novartis. View Insider Buying and Selling for Intellia Therapeutics.

How do I buy Intellia Therapeutics stock?

Shares of Intellia Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intellia Therapeutics' stock price today?

One share of Intellia Therapeutics stock can currently be purchased for approximately $17.43.


MarketBeat Community Rating for Intellia Therapeutics (NASDAQ NTLA)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  85 (Vote Outperform)
Underperform Votes:  63 (Vote Underperform)
Total Votes:  148
MarketBeat's community ratings are surveys of what our community members think about Intellia Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Intellia Therapeutics (NASDAQ:NTLA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $26.80 (53.76% upside)

Analysts' Ratings History for Intellia Therapeutics (NASDAQ:NTLA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/2/2017Chardan CapitalReiterated RatingBuy$19.00 -> $20.00LowView Rating Details
8/1/2017CannReiterated RatingHoldMediumView Rating Details
7/22/2017Jefferies Group LLCReiterated RatingBuy$36.00HighView Rating Details
7/18/2017Oppenheimer Holdings, Inc.Initiated CoverageMarket PerformHighView Rating Details
6/3/2017Credit Suisse GroupSet Price TargetBuy$24.00LowView Rating Details
5/15/2017WedbushReiterated RatingOutperform$25.00HighView Rating Details
1/5/2017Leerink SwannReiterated RatingOutperformN/AView Rating Details
9/28/2016Janney Montgomery ScottInitiated CoverageBuy$29.00N/AView Rating Details
(Data available from 8/24/2015 forward)

Earnings

Earnings History for Intellia Therapeutics (NASDAQ:NTLA)
Earnings by Quarter for Intellia Therapeutics (NASDAQ:NTLA)
Earnings History by Quarter for Intellia Therapeutics (NASDAQ NTLA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2017Q2 2017($0.42)($0.45)$5.83 million$5.90 millionViewN/AView Earnings Details
5/2/2017Q1 2017($0.34)($0.36)$5.30 million$6.22 millionViewN/AView Earnings Details
3/14/2017Q4 2016($0.21)($0.31)$5.63 million$5.63 millionViewN/AView Earnings Details
11/1/2016Q3 2016($0.22)($0.22)$4.55 million$4.90 millionViewN/AView Earnings Details
8/4/2016Q2 2016($0.10)($0.36)$6.34 million$4.21 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Intellia Therapeutics (NASDAQ:NTLA)
2017 EPS Consensus Estimate: ($1.67)
2018 EPS Consensus Estimate: ($1.95)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.35)($0.33)($0.34)
Q2 20174($0.45)($0.39)($0.42)
Q3 20174($0.54)($0.43)($0.49)
Q4 20174($0.64)($0.18)($0.43)
Q1 20182($0.54)($0.48)($0.51)
Q2 20182($0.57)($0.54)($0.56)
Q3 20182($0.55)($0.29)($0.42)
Q4 20182($0.61)($0.32)($0.47)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Intellia Therapeutics (NASDAQ:NTLA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Intellia Therapeutics (NASDAQ:NTLA)
Insider Ownership Percentage: 12.80%
Institutional Ownership Percentage: 47.20%
Insider Trades by Quarter for Intellia Therapeutics (NASDAQ:NTLA)
Institutional Ownership by Quarter for Intellia Therapeutics (NASDAQ:NTLA)
Insider Trades by Quarter for Intellia Therapeutics (NASDAQ:NTLA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/11/2017Venture Fund Ix L.P. AtlasMajor ShareholderSell150,000$16.24$2,436,000.00View SEC Filing  
3/10/2017Jean Francois FormelaDirectorSell21,132$13.91$293,946.12View SEC Filing  
5/11/2016Bros. Advisors Lp BakerInsiderBuy200,000$18.00$3,600,000.00View SEC Filing  
5/11/2016Carl L GordonDirectorBuy250,000$18.00$4,500,000.00View SEC Filing  
5/11/2016Institutes For Biomed NovartisMajor ShareholderBuy277,777$18.00$4,999,986.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Intellia Therapeutics (NASDAQ:NTLA)
Latest Headlines for Intellia Therapeutics (NASDAQ:NTLA)
Source:
DateHeadline
prnewswire.com logoInvestors: Covered-call reports for Box, Foot Locker, Fabrinet, Intellia Therapeutics and Tenet Healthcare
www.prnewswire.com - August 23 at 9:27 AM
finance.yahoo.com logoIntellia Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : NTLA-US : August 22, 2017
finance.yahoo.com - August 23 at 9:27 AM
americanbankingnews.com logoZacks: Analysts Anticipate Intellia Therapeutics, Inc. (NTLA) Will Post Quarterly Sales of $5.83 Million
www.americanbankingnews.com - August 18 at 3:02 AM
americanbankingnews.com logoIntellia Therapeutics, Inc. (NTLA) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - August 15 at 11:56 AM
bizjournals.com logoFormer GSK exec resigns from Intellia board due to 'conflict' - Boston Business Journal
www.bizjournals.com - August 11 at 7:00 AM
thestreet.com logoBiotech Movers: Second Quarter Results, Increased Outlook Send Horizon Pharma Shares Higher - TheStreet.com
www.thestreet.com - August 9 at 5:32 AM
americanbankingnews.com logoIntellia Therapeutics, Inc. (NTLA) to Post Q3 2017 Earnings of ($0.54) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - August 4 at 7:16 AM
americanbankingnews.com logoQ3 2017 EPS Estimates for Intellia Therapeutics, Inc. Lowered by Wedbush (NASDAQ:NTLA)
www.americanbankingnews.com - August 4 at 7:12 AM
americanbankingnews.com logoLeerink Swann Brokers Lower Earnings Estimates for Intellia Therapeutics, Inc. (NASDAQ:NTLA)
www.americanbankingnews.com - August 3 at 7:58 AM
americanbankingnews.com logoQ3 2017 EPS Estimates for Intellia Therapeutics, Inc. Increased by Oppenheimer Holdings (NTLA)
www.americanbankingnews.com - August 3 at 7:58 AM
americanbankingnews.com logoIntellia Therapeutics, Inc. (NASDAQ:NTLA) Given Buy Rating at Chardan Capital
www.americanbankingnews.com - August 2 at 2:02 PM
finance.yahoo.com logo Intellia Therapeutics Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 2 at 6:26 AM
americanbankingnews.com logoIntellia Therapeutics, Inc. (NASDAQ:NTLA) Announces Earnings Results, Misses Estimates By $0.03 EPS
www.americanbankingnews.com - August 1 at 2:20 PM
americanbankingnews.com logoIntellia Therapeutics, Inc. (NASDAQ:NTLA) Earns Hold Rating from Cann
www.americanbankingnews.com - August 1 at 12:56 PM
americanbankingnews.com logoIntellia Therapeutics, Inc. (NASDAQ:NTLA) Expected to Post Quarterly Sales of $5.83 Million
www.americanbankingnews.com - July 31 at 9:22 AM
americanbankingnews.com logoIntellia Therapeutics, Inc. (NTLA) Expected to Post Earnings of -$0.41 Per Share
www.americanbankingnews.com - July 29 at 4:20 PM
streetinsider.com logoIntellia Therapeutics (NTLA) Appoints Moncef Slaoui and Frank Verweil to Board - StreetInsider.com
www.streetinsider.com - July 27 at 5:31 AM
finance.yahoo.com logoIntellia Therapeutics Names Moncef Slaoui, Ph.D. and Frank Verwiel, M.D. to Its Board of Directors and Establishes a Science and Technology Committee
finance.yahoo.com - July 25 at 6:16 AM
americanbankingnews.com logoIntellia Therapeutics, Inc. (NASDAQ:NTLA) Earns Buy Rating from Jefferies Group LLC
www.americanbankingnews.com - July 22 at 1:32 PM
americanbankingnews.com logoIntellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - July 21 at 9:10 AM
americanbankingnews.com logoQ2 2017 Earnings Forecast for Intellia Therapeutics, Inc. Issued By Oppenheimer Holdings (NASDAQ:NTLA)
www.americanbankingnews.com - July 20 at 8:06 AM
seekingalpha.com logoBiotech Forum Daily Digest: Update On Approximately $5 Cytosorbents
seekingalpha.com - July 19 at 12:28 AM
americanbankingnews.com logoIntellia Therapeutics, Inc. (NASDAQ:NTLA) Coverage Initiated by Analysts at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - July 18 at 2:20 PM
americanbankingnews.com logoIntellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Market Perform Rating from Cann
www.americanbankingnews.com - July 17 at 7:44 PM
americanbankingnews.com logoVenture Fund Ix L.P. Atlas Sells 150,000 Shares of Intellia Therapeutics, Inc. (NTLA) Stock
www.americanbankingnews.com - July 11 at 7:53 PM
americanbankingnews.com logoIntellia Therapeutics, Inc. (NTLA) Stock Rating Upgraded by TheStreet
www.americanbankingnews.com - July 11 at 11:54 AM
americanbankingnews.com logoIntellia Therapeutics, Inc. (NTLA) Expected to Post Quarterly Sales of $5.61 Million
www.americanbankingnews.com - July 7 at 1:26 PM
americanbankingnews.com logo-$0.42 EPS Expected for Intellia Therapeutics, Inc. (NTLA) This Quarter
www.americanbankingnews.com - July 5 at 1:08 PM
americanbankingnews.com logoIntellia Therapeutics Inc (NTLA) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - June 26 at 8:54 AM
americanbankingnews.com logoJefferies Group Comments on Intellia Therapeutics Inc's Q2 2017 Earnings (NTLA)
www.americanbankingnews.com - June 26 at 7:10 AM
finance.yahoo.com logoIntellia Therapeutics, Inc. – Value Analysis (NASDAQ:NTLA) : June 22, 2017
finance.yahoo.com - June 23 at 8:34 AM
americanbankingnews.com logoIntellia Therapeutics Inc (NTLA) Earns Buy Rating from Analysts at Jefferies Group LLC
www.americanbankingnews.com - June 22 at 11:02 AM
finance.yahoo.com logoIntellia Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : NTLA-US : June 20, 2017
finance.yahoo.com - June 20 at 8:01 PM
streetinsider.com logoIntellia Therapeutics (NTLA) Receives Patent for CRISPR/Cas Genome Editing in China - StreetInsider.com
www.streetinsider.com - June 19 at 11:02 AM
finance.yahoo.com logoIntellia Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China
finance.yahoo.com - June 19 at 11:02 AM
americanbankingnews.com logoIntellia Therapeutics Inc (NTLA) Expected to Announce Quarterly Sales of $5.30 Million
www.americanbankingnews.com - June 11 at 9:20 AM
americanbankingnews.com logo-$0.41 Earnings Per Share Expected for Intellia Therapeutics Inc (NTLA) This Quarter
www.americanbankingnews.com - June 9 at 10:22 AM
finance.yahoo.com logoIntellia Therapeutics and San Raffaele University and Research Hospital to Combine CRISPR/Cas9 Genome Editing with Enhanced Cell Therapies to Fight Cancer
finance.yahoo.com - June 6 at 8:37 AM
nasdaq.com logoRegeneron Announces Positive Data on Carcinoma Candidate - Nasdaq
www.nasdaq.com - June 6 at 12:39 AM
americanbankingnews.com logoIntellia Therapeutics Inc (NTLA) PT Set at $24.00 by Credit Suisse Group AG
www.americanbankingnews.com - June 4 at 11:46 PM
americanbankingnews.com logoIntellia Therapeutics Inc (NTLA) Short Interest Update
www.americanbankingnews.com - June 4 at 11:34 AM
finance.yahoo.com logoIntellia Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : NTLA-US : May 26, 2017
finance.yahoo.com - May 26 at 7:52 PM
americanbankingnews.com logoIntellia Therapeutics' (NTLA) "Outperform" Rating Reiterated at Wedbush
www.americanbankingnews.com - May 15 at 9:34 PM
finance.yahoo.com logoIntellia Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : NTLA-US : May 15, 2017
finance.yahoo.com - May 15 at 10:07 AM
americanbankingnews.com logoZacks: Analysts Expect Intellia Therapeutics Inc (NTLA) Will Announce Earnings of -$0.41 Per Share
www.americanbankingnews.com - May 15 at 10:00 AM
finance.yahoo.com logoIntellia Therapeutics Announces Progress with CRISPR/Cas9 at the American Society of Gene & Cell Therapy Annual Meeting
finance.yahoo.com - May 14 at 10:41 AM
americanbankingnews.com logoQ2 2017 EPS Estimates for Intellia Therapeutics Inc Reduced by Leerink Swann (NTLA)
www.americanbankingnews.com - May 5 at 7:16 AM
americanbankingnews.com logoQ2 2017 EPS Estimates for Intellia Therapeutics Inc Cut by Wedbush (NTLA)
www.americanbankingnews.com - May 5 at 7:16 AM
americanbankingnews.com logoResearch Analysts Issue Forecasts for Intellia Therapeutics Inc's Q1 2018 Earnings (NTLA)
www.americanbankingnews.com - May 4 at 5:50 PM
finance.yahoo.com logoIntellia Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : NTLA-US : May 4, 2017
finance.yahoo.com - May 4 at 11:18 AM

Social

Chart

Intellia Therapeutics (NTLA) Chart for Thursday, August, 24, 2017

This page was last updated on 8/24/2017 by MarketBeat.com Staff